Lexeo Therapeutics Launches Dual Funding Strategy with Public Offering and Private Placement
Lexeo Therapeutics has announced a dual approach to raise funds, with an underwritten public offering and a private placement to Balyasny Asset Management. The company's shares are currently trading at $8.54 after hours, down 2.62%.
Lexeo Therapeutics, listed on the NASDAQ as LXEO, has kicked off an underwritten public offering of its common stock and pre-funded warrants. The size and timing of these offerings will be determined by market conditions. Notably, the private placement to Balyasny Asset Management is not dependent on the completion of the public offering. This strategic move allows Lexeo to secure funds from both public investors and the asset management firm in a private deal.
Lexeo Therapeutics is pursuing a dual funding strategy with a public offering and a private placement to Balyasny Asset Management. The company's stock price has dipped slightly in after-hours trading, but the offerings provide opportunities for both public and private investors to support Lexeo's growth.